Impairment of nuclear factor-κB activation increased glutamate excitotoxicity in a motoneuron-neuroblastoma hybrid cell line expressing mutant (G93A) Cu/Zn-superoxide dismutase

Journal of Neuroscience Research

Volumn 88, Issue 11, 2010, Pages 2494-2503

  Pyo, Jung Soo ^a   Ko, Young San ^b   Kim, Woo Ho ^b   Kim, Manho ^b   Lee, Kwang Woo ^b   Nam, Seon Young ^c   Chung, Hee Yong ^d   Cho, Sung Jin ^a   Baik, Tai Kyoung ^a   Lee, Byung Lan ^b  

^a Eulji University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Korea Hydro & Nuclear Power Co   (South Korea)

^d Hanyang University College of Medicine   (South Korea)

Author keywords

Familial amyotrophic lateral sclerosis; Glutamate excitotoxicity; Motor neurons; Mutant Cu Zn superoxide dismutase; Nuclear factor B

Indexed keywords

CASPASE 3; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMIC ACID; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNAPTOTAGMIN I; X LINKED INHIBITOR OF APOPTOSIS; 4',6 DIAMIDINO 2 PHENYLINDOLE; FLUORESCENT DYE; GLUTAMATE RECEPTOR; INDOLE DERIVATIVE; LUCIFERASE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVITY; EXCITOTOXICITY; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HYBRID CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOTONEURON; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BIOTRANSFORMATION; CELL DEATH; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; CYTOPLASM; DRUG EFFECTS; ENZYMOLOGY; GENE VECTOR; GENETICS; METABOLISM; MUTATION; NEUROBLASTOMA; PHYSIOLOGY; RETROVIRUS; TOXICITY;

ANIMALS; BIOTRANSFORMATION; CASPASE 3; CELL DEATH; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; CYTOPLASM; FLUORESCENT DYES; GENETIC VECTORS; GLUTAMIC ACID; HUMANS; HYBRID CELLS; IMMUNOHISTOCHEMISTRY; INDOLES; LUCIFERASES; MICE; MICE, TRANSGENIC; MOTOR NEURONS; MUTATION; NEUROBLASTOMA; NF-KAPPA B; RECEPTORS, GLUTAMATE; RETROVIRIDAE; SUPEROXIDE DISMUTASE;

EID: 77955354678     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22397     Document Type: Article

References (35)

1. Bonizzi G, Karin M. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-288. (Pubitemid 38610351)
2. Casciati A, Ferri A, Cozzolino M, Celsi F, Nencini M, Rotilio G, Carrì MT. 2002. Oxidative modulation of NF-κB in human cells expressing mutant fALS-typical superoxide dismutases. J Neurochem 83:1019-1029.
3. Chen X, Kandasamy K, Srivastava RK. 2003. Differential roles of RelA (p65) and c-Rel subunits of NF-κB in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 63:1059-1066.
4. Dunlop J, Beal McIlvain H, She Y, Howland DS. 2003. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 23:1688-1696. (Pubitemid 36314724)
5. Fan W, Cooper NG. 2009. Glutamate-induced NFkappaB activation in the retina. Invest Ophthalmol Vis Sci 50:917-925.
6. Flanagan SW, Anderson RD, Ross MA, Oberley LW. 2002. Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J Neurochem 81:170-177.
7. Gelinas DF. 2000. Riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord 1(Suppl 4):3-4.
8. Gilmore TD. 1999. The Rel/NF-κB signal transduction pathway: introduction. Oncogene 18:6842-6844.
9. Gurney ME. 1997. Transgenic animal models of familial amyotrophic lateral sclerosis. J Neurol 244:S15-20.
10. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai P, Sufit RL, Siddique T. 1994. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264: 1772-1775. (Pubitemid 24227760)
11. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED. 1996. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39:147-157.
12. Harris J, Olière S, Sharma S, Sun Q, Lin R, Hiscott J, Grandvaux N. 2006. Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKK epsilon. J Immunol 177:2527-2535.
13. Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, Erickson J, Kulik J, DeVito L, Psaltis G, DeGennaro LJ, Cleveland DW, Rothstein JD. 2002. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A 99:1604-1609.
14. Huang Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. 2005. NF-κB precursor, p105, and NF-κB inhibitor, I-κBγ, are both elevated in Alzheimer disease brain. Neurosci Lett 373:115-118. (Pubitemid 39572972)
15. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, Hirsch EC. 1997. Nuclear traslocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc Natl Acad Sci U S A 94:7531-7536.
16. Ishige K, Tanaka M, Arakawa M, Saito H, Ito Y. 2005. Distinct nuclear factor-κB/Rel proteins have opposing modulatory effects in glutamate-induced cell death in HT22 cells. Neurochem Int 47:545-555.
17. Jiang YM, Yamamoto M, Kobayashi Y, Yoshihara T, Liang Y, Terao S, Takeuchi H, Ishigaki S, Katsuno M, Adachi H, Niwa J, Tanaka F, Doyu M, Yoshida M, Hashizume Y, Sobue G. 2005. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol 57:236-251.
18. Karin M, Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18:621-663. (Pubitemid 30365393)
19. Kim WH, Schnaper HW, Nomizu M, Yamada Y, Kleinman HK. 1994. Apoptosis in human fibrosarcoma cells is induced by a multimeric synthetic Tyr-Ile-Gly-Ser-Arg (YIGSR)-containing polypeptide from laminin. Cancer Res 54:5005-5010.
20. Kunst CB. 2004. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet 75:933-947. (Pubitemid 39532065)
21. Lee CH, Jeon YT, Kim SH, Song YS. 2007. NF-κB as a potential molecular target for cancer therapy. Biofactors 29:19-35.
22. Lee KW, Kim HJ, Sung JJ, Park KS, Kim M. 2002. Defective neurite outgrowth in aphidicolin/cAMP-induced motor neurons expressing mutant Cu/Zn superoxide dismutase. Int J Dev Neurosci 20:521-526.
23. Mattson MP, Goodman Y, Luo H, Fu W, Furukawa K. 1997. Activation of NF-κB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J Neurosci Res 49:681-697.
24. Memet S. 2006. NF-κB functions in the nervous system: from development to disease. Biochem Pharmacol 72:1180-1195. (Pubitemid 44465848)
25. Miller RG, Mitchell JD, Lyon M, Moore DH. 2003. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 4:191-206.
26. Nam SY, Jung GA, Hur GC, Chung HY, Kim WH, Seol DW.Lee BL. 2003. Up-regulation of FLIPS by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94:1066-1073.
27. Pizzi M, Spano P. 2006. Distinct roles of diverse nuclear factor-κB complexes in neuropathological mechanisms. Eur J Pharmacol 545:22-28.
28. Pizzi M, Goffi F, Boroni F, Benarese M, Perkins SE, Liou HC, Spano P. 2002. Opposing roles for NF-κB/Rel factors p65 and c-Rel in the modulation of neuron survival elicited by glutamate and interleukin-1b. J Biol Chem 277:20717-20723.
29. Pizzi M, Sarnico I, Boroni F, Benarese M, Steimberg N, Mazzoleni G, Dietz GP, Bähr M, Liou HC, Spano PF. 2005. NF-κB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. Cell Death Differ 12:761-772.
30. Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, Wong LF, Bilsland LG, Greensmith L, Kingsman SM, Mitrophanous KA, Mazarakis ND, Azzouz M. 2005. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11:429-433.
31. Salvesen GS, Duckett CS. 2002. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3:401-410.
32. Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, Mizuno T, Tohyama M. 1999. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFκB activation in primary hippocampal neurons. J Biol Chem 274:8531-8538. (Pubitemid 29164643)
33. Tergaonkar V. 2006. NFκB pathway: a good signaling paradigm and therapeutic target. Int J Biochem Cell Biol 38:1647-1653.
34. Viatour P, Merville MP, Bours V, Chariot A. 2005. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 30:43-52. (Pubitemid 40093740)
35. Wang X, Gorospe M, Huang Y, Holbrook NJ. 1997. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 15: 2991-2997. (Pubitemid 28008992)